KARDEGIC 75 mg

DRUG8 trials

Sponsors

Centre Hospitalier Universitaire De Saint Etienne, St Antonius Hospital, Centre Hospitalier Universitaire De Caen Normandie, Assistance Publique Hopitaux De Marseille, Centre Hospitalier Regional Universitaire

Conditions

All adult patients with successful transfemoral trans-aortic valve implantation (TAVI ) for symptomatic aortic stenosis (AS) with no other indication for long term antiplatelet or anticoagulant therapyElderly patients ≥ 65 years successfully treated with percutaneous coronary intervention (PCI) with ≥ 1 drug-eluting stent for acute or chronic coronary syndromeImmune thRombocytopeniaMetastatic colorectal canceracute venous thromboembolism eventaortic valve stenosischronically occluded coronary arterymetastatic colorectal cancer carcinoma

Phase 2

Short versus long antiplatelet therapy after TAVI

RecruitingCTIS2023-508208-40-00

Centre Hospitalier Universitaire De Caen NormandieAll adult patients with successful transfemoral trans-aortic valve implantation (TAVI ) for symptomatic aortic stenosis (AS) with no other indication for long term antiplatelet or anticoagulant therapy

Start: 2024-11-21Target: 1400Updated: 2025-05-07

REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma An open-label randomized phase II-III study

Not yet recruitingCTIS2024-516709-22-00

Centre Hospitalier Regional Universitairemetastatic colorectal cancer carcinoma

Target: 94Updated: 2025-10-08

Phase 3

Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE

RecruitingCTIS2022-500974-33-00

Centre Hospitalier Universitaire De Saint Etienneacute venous thromboembolism event

Start: 2023-08-12Target: 1400Updated: 2025-04-25

CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers

RecruitingCTIS2023-509761-21-00

Centre Hospitalier Regional UniversitaireMetastatic colorectal cancer

Start: 2024-07-08Target: 174Updated: 2024-08-28

Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentre, randomized study comparing two durations of dual antiplatelet therapy

RecruitingCTIS2023-508148-23-01

Assistance Publique Hopitaux De Marseillechronically occluded coronary artery

Start: 2024-12-02Target: 660Updated: 2025-04-15

Aspirin in immune thrombocytopenia patients with cardiovascular disease

CompletedCTIS2024-513846-13-00

Centre Hospitalier Universitaire De ToulouseImmune thRombocytopenia

Start: 2023-01-16End: 2025-01-15Target: 10Updated: 2024-05-28

Phase 4

Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in non-atrial fibrillation patients after transcatheter aortic valve implantation: a pragmatic, international, multicentre, randomized clinical trial (POPular ATLANTIS trial)

RecruitingCTIS2023-504637-42-01

St Antonius Hospitalaortic valve stenosis

Start: 2023-12-21Target: 2600Updated: 2025-08-25

Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneous coronary intervention.

Not yet recruitingCTIS2023-507545-28-00

Centre Hospitalier Universitaire De Caen NormandieElderly patients ≥ 65 years successfully treated with percutaneous coronary intervention (PCI) with ≥ 1 drug-eluting stent for acute or chronic coronary syndrome

Target: 1700Updated: 2025-03-27